PROSPECTS FOR USING BIOACTIVE BACTERIAL HYDROLYSATES FOR NUTRITIONAL SUPPLEMENTATION OF PEOPLE WITH IMMUNE SYSTEM DISORDERS
DOI:
https://doi.org/10.15673/2073-8684.31/2015.44263Keywords:
immunotropic properties, bacteria, hydrolysates, peptidoglycans, muramyl dipeptides, enzymesAbstract
This article provides survey information about immunotropic properties of peptidoglycan fragments of bacterial cell walls – muramyl dipeptide (MDP) and its derivatives. MDP is capable of activating inborn and adaptive immunity systems, stimulating antimicrobial activity, immunological surveillance, activating immune competent cells and inducing cytokine synthesis. The article presents prospects for using bacterial hydrolysates containing substances of muramyl peptide type as functional immunotropic ingredients as a part of dietary supplements and foods. The screening of potential microbial objects for receiving MDP, analysis of the existing products on the basis of MDP as well as analysis of the known methods for producing microbial hydrolysates were carried out.
It is founded that in order to obtain bacterial hydrolysates the use of microorganism mixture is considered appropriate for receiving functional ingredients with wide spectrum of biological activities. In order to obtain immunotropic functional ingredients the bacterial cell disintegration should be performed by mild enzymatic method with using a combination of enzymes having proteolytic (trypsin, pancreatin) and muramidase (lysozyme) activity.
References
Knotigová, Pavlína Turánek [et al.]. (2015). Molecular Adjuvants Based on Nonpyrogenic Lipophilic Derivatives of norAbuMDP/GMDP Formulated in Nanoliposomes: Stimulation of Innate and Adaptive Immunity. Pharmaceutical Research. 32, 4, 1186. DOI: 10.1007/S11095-014-1516-y
Traub, S. [et al.]. (2006). MDP and other muropeptides – direct and synergistic effects on the immune system. J. Endotoxin Res, 12, 2, 69–85.
Qingshan, Lv (2012). MDP Up-Regulates the Gene Expression of Type I Interferons in Human Aortic Endothelial Cells. Molecules, 17, 3599-3608; doi:10.3390/molecules17043599
Kelly, C.D. [et al.] (2007). Rapid generation of an anthrax immunotherapeutiс from goats using a novel non-toxic muramyl dipeptide adjuvant. Immune Based Ther. Vaccines, 5, 11,1–8. http://www.jibtherapies. com/ con-tent/5/1/11.
Molohova, E.I. Sorokina, Yu.V. (2011). Razrabotki otechestvennyh metabolitnyh probiotikov i ih standartizaciya. Sibirskii medicinskii zhurnal, 26, 5, 1, 29 –33.
Polovinkina, V.S. Markov, E.Yu. (2012). Immunoad'yuvantnye svoistva muramildipeptida. Byulleten' VSNC SO RAMN, 83, 149–153
Marc A. Boudreau. Jed F. Fisher, Shahriar Mobashery (2012). Messenger Functions of the Bacterial Cell Wall-derived Muropeptides. Biochemistry, 51, 14, 2974
Nan, Zhao [et al.] (2011). New muramyl dipeptide (MDP) mimics without the carbohydrate moiety as potential adjuvant candidates for a therapeutic hepatitis B vaccine (HBV). Bioorganic Medicinal Chemistry Letters, 21, 14, 4292
Andronova, T., Pinegin, B. (2006). Muramildipeptidy – immunotropnye lekarstvennye sredstva novogo pokoleniya. Venerolog, 6, 11–15.
Pinegin, B.V., Andronova, T.M., Karsonova, M.I. (1997). Preparaty muramildipeptidnogo ryada – immunotropnye lekarstvennye sredstva novogo pokoleniya. INTERNATIONAL JOURNAL ON IMMUNOREHABILITATION, 6, JUNE. http://peptek.ru/PRODUCT/LICOPID/Articles/ITLS.html
Telishevskaya, L.Ya. (2000). Belkovye gidrolizaty. Poluchenie, sostav, primenenie. Agrarnaya nauka, Moskva.
Gavrilin, M.V., Sen'chukova, G.V., Senchenko, S.P. (2007). Vybor optimal'nyh uslovii polucheniya gidrolizatov molochnokislyh bakterii termokislotnym sposobom. Him.-farm. Zhurn, 41, 2. 54–56.
Senchenko, S.P. (2006). Razrabotka metodov analiza i optimizaciya sostava lekarstvennogo preparata na osnove gidrolizata molochnokislyh bakterii: avtoref. dis. … kand. farm. nauk. Pyatigorsk, 24 s.
Senchenko, S.P. Samoilov, V.A., Gostisheva, N.M., Sen'chukova, G.V., Gavrilin M.V. (2005). Izuchenie sostava preparata, poluchennogo na osnove gidrolizata molochnokislyh bakterii. Him.-farmac. Zhurn, 39, 3,51-55
Pat. na korisnu model' RU (11) 2304167 (13) C2 (51) MPK C12P21/00 (2006.01) Sposob poucheniya glikopeptidov i glikopeptidnyi produkt, poluchennyi etim sposobom, dya ispol'zovaniya v medicine / Ermolaev E, D., Sofronova O. V., Orlov N. S., Polyakova L. L., Peshkova L. M.// Zayavitel': Obshestvo s ogranichennoi otvetstvennost'yu "MEDBIOFARM-BIOTEH". – Zayavka: 2005128653/13, 15.09.2005; opubl. 20.03.2007
Garanyan, G.S. Hanferyan, R.A., Oganesyan, E.T. (2010). Himicheskoe obosnovanii i biologicheskoe issledovanie gidrolizata na osnove kul'tur molochnokislyh bakterii. Him.-farmac. Zhurn.,44, 8, 46–49.
Kalyuzhin, O.V. [i dr.] (2008). Biologicheskaya aktivnost' anomernyh par lipofil'nyh glikozidov N-acetilmuramil-Lalanin-D izoglutamina. Byul. eksp. biol. med., 145, 5. 561–564.
Zemlyakov, A.E. [i dr.] (2008). b-Dialkilmetilglikozidy N-acetilmuramoil-L-alanil-D-izoglutamina: sintez, protektivnoe antiinfekcionnoe i citotoksicheskoe deistvie. Bioorgan. Himiya, 34, 1, 114-120.
Kalyuzhin, O.V. [i dr.] (2002). Deistvie glikozidov muramildipeptida na proliferaciyu limfocitov i vyrabotku imi interleikina-2. Byul. eksp. biol. Med.,134, 8, 186–190.
Kalyuzhin, O.V. [i dr.] (2009). Deistvie cikloalkilglikozidov muramildipeptida na antibakterial'nuyu rezistentnost' myshei i produkciyu citokinov mononuklearami cheloveka. Byul. eksp. biol. med., 148, 10, 426–429.
Kalyuzhin, O.V. [i dr.] (2003). Stimulyaciya rezistentnosti myshei k bakterial'noi infekcii glikozidami muramildipeptida. Byul. eksp. biol. med., 135, 5, 531–535.
Darcissac, E.C. [et al.] (2000). The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells. J. Virol., 74, 17, 7794–7802.
Vinnickii, L.I. [i dr.] (1997). Otechestvennyi immunomodulyator novogo pokoleniya likopid v kompleksnom lechenii i profilaktike infekcionnyh oslozhnenii v hirurgicheskoi praktike. Vestnik RAMN, 11, 46–48.
Karaulov, A.V. [i dr.] (2002). Proizvodnye muramildipeptida v klinike. Aktual'nye voprosy klinicheskoi mediciny, 2, 93–100.
Lidija Barišić, Maja Roščić, Monika Kovačević, Mojca Čakić Semenčić, Štefica Horvat, Vladimir Rapić (2011). The first ferrocene analogues of muramyldipeptide. Carbohydrate Research, 346, 5, 678
Meshcheryakova, E. A., Andronova, T. M., Ivanov, V. T. (2010). Protein interaction network and signaling path-ways activated by muramyl peptides, Russian Journal of Bioorganic Chemistry, , 36, 5, 535 DOI: 10/1134/S1068 1620 10050018
Rogan, D., Fumuso, E., Rodríguez, E., Wade, J., Sánchez Bruni, S.F (2007). Use of a Mycobacterial Cell Wall Ex-tract (MCWE) in Susceptible Mares to Clear Experimentally Induced Endometritis With Streptococcus zooepidemicus. Journal of Equine Veterinary Science, 27, 3, 112 DOI: http://dx.doi.org/10.1016/j.jevs.2007.01.010.
Shenderov, B.A. (2001)/ Medicinskaya mikrobnaya ekologiya i funkcional'noe pitanie : v 3 t. – M. : GRANT',. – T. 3. Probiotiki i funkcional'noe pitanie. – 288 s.
Markov, E.Yu. [i dr.] (2004). Protektivnaya aktivnost' subkletochnyh frakcii Yersinia pestis pri eksperimental'noi chume u belyh myshei. Byul. VSNC SO RAMN, 2, 1, 123–127.
Polovinkina, V.S. [i dr.] (2011). Vliyanie subkletochnyh frakcii chumnogo mikroba na produkciyu citokinov immunokompetentnymi kletkami belyh myshei. Byul. VSNC SO RAMN, 3,. 1, 217–220.
Ermolenko, E.I., Chernysh, A.Yu., Marcinkovskaya, I.V. i dr. (2007). Vliyanie probioticheskih enterokokkov na rost Streptococcus agalactiae. Zhurn. mikrobiologii, immunologii i epidemiologii, 5, 73–77.
Neschislyaev, V.A., Molohova, E.I., Chistohina, L.P. i dr. (2007). K voprosu razrabotki probioticheskih preparatov iz kul'tural'noi zhidkosti laktobakterii. Klinicheskoe pitanie. 1–2, 55.
Volkov, M.Yu., Tkachenko, E.I., Vorobeichikov, E.V. i dr. (2007). Metabolity Bacillus subtilis kak novye perspektivnye probioticheskie preparaty. Zhurn. mikrobiologii, immunologii i epidemiologii, 2, 75–79
